Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel
Moldiag Erkrankungen Gene Support Kontakt

Hyperthyreose

Als Hyperthyreose wird eine Krankheit mit zu starker Sekretion von Schilddrüsenhormon bezeichnet. Genetisch bedingte Hyperthyreosen können mit oder ohne Struma einhergehen.

Gliederung

Störungen des Schilddrüsenhormonsystems
Dysalbuminämische Hyperthyroxinämie
Hyperthyreose
Basedow-Krankheit
GC
Familiäre Schwangerschaftshyperthyreose
TSHR
McCune-Albright-Syndrom
GNAS
Neigung zur thyreotoxischen periodischen Paralyse 1
CACNA1S
Nicht-autoimmunbedingte Hyperthyreose
TSHR
Hypothyreose
Neigung zu autoimmunbedingten Schilddrüsenerkrankungen
Schilddrüsenhormonresistenz
Schilddrüsenkarzinome

Referenzen:

1.

Au KS et al. (1972) Thyrotoxic periodic paralysis. Periodic variation in the muscle calcium pump activity.

external link
2.

Simmonds MJ et al. (2005) Regression mapping of association between the human leukocyte antigen region and Graves disease.

external link
3.

Sutherland A et al. (2007) Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility.

external link
4.

Brand OJ et al. (2009) Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease.

external link
5.

None (1945) The hereditary and familial aspects of exophthalmic goitre and nodular goitre.

external link
6.

Barbesino G et al. (1998) Linkage analysis of candidate genes in autoimmune thyroid disease. II. Selected gender-related genes and the X-chromosome. International Consortium for the Genetics of Autoimmune Thyroid Disease.

external link
7.

Heward JM et al. (1998) Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study.

external link
8.

Ryan DP et al. (2010) Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis.

external link
9.

Kusakabe T et al. (1976) Thyrotoxic periodic paralysis: a peculiar case with unusual dystonic behavior and variable relations of paralysis to serum potassium levels.

external link
10.

Ueda H et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.

external link
11.

Yeung RT et al. (1974) Thyrotoxic periodic paralysis. Effect of propranolol.

external link
12.

Layzer RB et al. (1974) Periodic paralysis caused by abuse of thyroid hormone.

external link
13.

Bernard JD et al. (1972) Thyrotoxic periodic paralysis in Californians of Mexican and Filipino ancestry.

external link
14.

McFadzean AJ et al. (1967) Periodic paralysis complicating thyrotoxicosis in Chinese.

external link
15.

Kilpatrick RE et al. (1994) Thyrotoxic hypokalemic periodic paralysis: report of four cases in black American males.

external link
16.

Sternberg D et al. (2003) Lack of association of the potassium channel-associated peptide MiRP2-R83H variant with periodic paralysis.

external link
17.

Jurkat-Rott K et al. (2004) Periodic paralysis mutation MiRP2-R83H in controls: Interpretations and general recommendation.

external link
18.

None (2006) Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge.

external link
19.

Kretowski A et al. (2003) Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease.

external link
20.

Kung AW et al. (2004) Association of novel single nucleotide polymorphisms in the calcium channel alpha 1 subunit gene (Ca(v)1.1) and thyrotoxic periodic paralysis.

external link
21.

Chu X et al. (2011) A genome-wide association study identifies two new risk loci for Graves' disease.

external link
22.

Pani MA et al. (2002) A polymorphism within the vitamin D-binding protein gene is associated with Graves' disease but not with Hashimoto's thyroiditis.

external link
23.

Chen CR et al. (2003) The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

external link
24.

Hiratani H et al. (2005) Multiple SNPs in intron 7 of thyrotropin receptor are associated with Graves' disease.

external link
25.

Dechairo BM et al. (2005) Association of the TSHR gene with Graves' disease: the first disease specific locus.

external link
26.

None (1985) Familial "hashitoxic' periodic paralysis.

external link
27.

Akamizu T et al. (2003) Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients.

external link
28.

Barbero P et al. (2004) Choanal atresia associated with prenatal methimazole exposure: three new patients.

external link
29.

Ban Y et al. (2000) Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population.

external link
30.

Vaidya B et al. (1999) The cytotoxic T lymphocyte antigen-4 is a major Graves' disease locus.

external link
31.

Chen QY et al. (1999) HLA-DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective.

external link
32.

Chen QY et al. (2000) The human leukocyte antigen HLA DRB3*020/DQA1*0501 haplotype is associated with Graves' disease in African Americans.

external link
33.

Marcocci C et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.

external link
34.

Hermenegildo C et al. (2002) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients.

external link
35.

Robertson DM et al. (2003) Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy.

external link
36.

MARTIN L et al. (1951) The hereditary and familial aspects of toxic nodular goitre (secondary thyrotoxicosis).

external link
37.

Wikipedia Artikel

Wikipedia DE (Hyperthyreose) external link
Update: 14. August 2020
Copyright © 2005-2020 Zentrum für Nephrologie und Stoffwechsel, Dr. Mato Nagel
Albert-Schweitzer-Ring 32, D-02943 Weißwasser, Deutschland, Tel.: +49-3576-287922, Fax: +49-3576-287944
Seitenüberblick | Webmail | Haftungsausschluss | Datenschutz